Navigation Links
Noven Announces FDA Advisory Committee Vote on Investigational Low-Dose Mesylate Salt of Paroxetine (LDMP) for Vasomotor Symptoms Associated with Menopause
Date:3/4/2013

MIAMI, FL and NEW YORK, NY, March 4, 2013 /PRNewswire/ -- Noven Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) Reproductive Health Drugs Advisory Committee voted 10 to 4 that the overall risk/benefit profile of low-dose mesylate salt of paroxetine (LDMP; 7.5 mg/day) is not acceptable to support approval. LDMP is an investigational nonhormonal treatment specifically developed for moderate to severe vasomotor symptoms (VMS) associated with menopause.

Additionally, the committee voted:

  • 7 to 7 that, based on pre-specified analyses, there is sufficient evidence to conclude that LDMP is effective in treating moderate to severe VMS associated with menopause; and
  • 10 to 4 that, based on pre-specified analyses, there is not sufficient evidence to conclude that the change from baseline in VMS frequency is clinically meaningful to women.

The FDA is not bound by the recommendations of its advisory committees, but will consider their guidance during the ongoing review of the New Drug Application (NDA) that was submitted for LDMP in August 2012. The scheduled Prescription Drug User Fee Act (PDUFA) action date for LDMP is June 28, 2013.

"As conveyed during Noven's presentation, we believe our clinical trial data support LDMP as a safe, effective nonhormonal treatment option offering clinical benefit to menopausal women," said Joel S. Lippman , M.D., Noven's Executive Vice President – Product Development and Chief Medical Officer. "While we are disappointed in today's outcome, we appreciate the discussion and will work closely with the FDA as it completes its ongoing evaluation."

Moderate to severe VMS affect approximately 24 million menopausal women in the United States and approximately two-thirds are not currently trea
'/>"/>

SOURCE Noven Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Accepts Novens NDA For An Investigational Nonhormonal Therapy For Menopausal Vasomotor Symptoms
2. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
3. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
4. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
5. Misonix Announces New Distribution Agreement For Panama
6. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
9. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
10. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
11. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/5hkm2f/medical_oxygen ) has ... - Global Strategic Business Report" report to their ... for Medical Oxygen Systems in US$ Thousands by the ... & Regulators, and Oxygen Conserving Devices. The report provides ... , Japan , ...
(Date:4/17/2015)... 17, 2015 Steven Rash , the CEO ... its operating subsidiary American Seed & Oil Company, presented ... investors yesterday in New York City.  Mr. Rash,s presentation ... American Seed & Oil Company has recently announced the ... Hemp Seed Foods , the EpiVape , and ...
(Date:4/17/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/7qs3dw/corporate ) has ... Pharma in 2014 - a Perspective of Diabetes Patient ... This independent study, funded by the author, ... interest in diabetes on the corporate reputation of 14 ... a whole) in 2014. The results from the respondent ...
Breaking Medicine Technology:Medical Oxygen Systems - 2015 Global Strategic Business Report Featuring Leading Players, Caire, Invacare & Philips Respironics 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 3Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 2Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 3Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 4Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 5
... & NEW DELHI, India--(BUSINESS WIRE)--Jun 21, 2007,- The ... today announced that Phase 3 research,related to its ... published in the current issue of The,New England ... the medicine paromomycin is safe, effective, and well ...
... MRSA,in Healthcare Facilities, WASHINGTON, June 21, 2007 /PRNewswire-USNewswire/ -- The,following ... WHAT:, -- First nationwide study of the ... aureus (MRSA), a virulent multi-drug resistant organism, ... -- MRSA prevalence study findings significantly exceed previous estimates, ...
Cached Medicine Technology:Research on New Treatment for Neglected Disease Published in The,New England Journal of Medicine 2Research on New Treatment for Neglected Disease Published in The,New England Journal of Medicine 3Research on New Treatment for Neglected Disease Published in The,New England Journal of Medicine 4Nationwide MRSA Prevalence Study to Demonstrate Full Scope of,'Superbug' Threat Facing U.S. Healthcare Facilities and Patients 2
(Date:4/17/2015)... April 17, 2015 “We have seen healing, ... the past and present,” said Chaplain Shawn Kafader of Friendship ... felt like they had anything to contribute have created beautiful ... overseen a new art therapy program that was launched to ... Masters student from School of the Art Institute in Chicago, ...
(Date:4/17/2015)... In Defense of Christians (IDC) Executive Director ... April 15th, the European Parliament joined its voice with ... Armenian Genocide, “paying tribute, on the eve of the ... Armenian victims who perished in the Ottoman Empire.” ... this timely and needed recognition of a tragic episode ...
(Date:4/17/2015)... DC (PRWEB) April 17, 2015 Representatives ... HHT Diagnoses and Treatment Act HR 1849 in congress ... diagnosis rates and treatment for patients with the genetic ... in the past, would be the first to create ... and appropriate treatment of hereditary hemorrhagic telangiectasia. This would ...
(Date:4/17/2015)... Hills, California (PRWEB) April 17, 2015 ... stands above in his new offering of platelet-rich plasma ... Orthopedic Sports Medicine (MOSM) is known for its ... Dr. Meier brings extensive surgical experience lacking in many ... and stem cell treatments are utilized for pain management ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Most dental ... dental restoration units are made overseas by foreign dental ... domestic labs remain unregulated in more than 40 states ... National Association of Dental Laboratories has created ... raise awareness among patients about the consequences that could ...
Breaking Medicine News(10 mins):Health News:Healing At Friendship Village Due To Art Therapy 2Health News:In Defense of Christians Condemns Armenian Genocide 2Health News:In Defense of Christians Condemns Armenian Genocide 3Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3Health News:National Association Urges Transparency in Dental Industry 2
... TORONTO, Nov. 12 /PRNewswire-FirstCall/ - Transition Therapeutics Inc.,("Transition" or ... hold a,conference call on Wednesday, November 14, 2007 at ... financial results. Dr. Tony Cruz, Chairman,and Chief Executive Officer ... its financial results for this period in a press ...
... Incorporated,(Nasdaq: VPHM ) today announced that the ... Medicines Agency (EMEA) has granted orphan,drug designation for ... patients with impaired cell-mediated immunity. The EMEA,s,"Orphan Medicinal ... drugs which may provide significant benefit to patients,suffering ...
... spirometry to clinical exams benefits those with symptoms , MONDAY, ... diagnosing and treating the lung illness known as stable ... American College of Physicians (ACP). , COPD, typically caused ... affects more than 5 percent of American adults and is ...
... Now has,selected its $7,500 Grand Prize winner in its ... walks away with the big prize,after a 3-month competition ... will receive $250 in the contest. The winning video ... "Brendan Hayward captured, in just 30 seconds, what ...
... Mich., Nov. 12 Leading health care risk,management ... third,quarter results for the period ended Sept. 30, ... quarter and first nine months of the year. ... medical,professional liability insurance and integrated risk management products,and ...
... Medical,Association (AMA) proudly presented Portland physician Richard Allen, ... its semi-annual,policy-making meeting. Dr. Allen is the first ... for meritorious service in the science and art,of ... advancing medical education," said,AMA President Ron Davis, M.D. ...
Cached Medicine News:Health News:Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2008 Financial Results on Wednesday, November 14, at 8:30 A.M. EST 2Health News:ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM) 2Health News:ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM) 3Health News:ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM) 4Health News:New Guideline Targets Treatment of Stable COPD 2Health News:Psoriasis Cure Now Video Contest $7,500 Grand Prize Winner Announced 2Health News:FinCor Holdings Posts Double-Digit Increases in Revenue and Net Income for Third Quarter 2Health News:FinCor Holdings Posts Double-Digit Increases in Revenue and Net Income for Third Quarter 3Health News:Portland Physician Wins AMA Distinguished Service Award 2
... The PipetBoy Pipettor is light as a feather ... aspiration speed can be continuously adjusted. The pipette ... be autoclaved. Two dosing knobs enable fine dosing ... plastic an/or glass pipettes from 0.1 to 100 ...
Precise, safe, and fatigue-free series pipetting using graduated pip...
Inquire...
Inquire...
Medicine Products: